We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares of Neurotrope Bioscience (NTRP - Free Report) opened more than 46% lower on Monday after the company released the results of its clinical trial for bryostatin, a drug candidate for patients with moderate to severe Alzheimer’s.
Although Neurotrope’s press release claims “positive top-line results” in Phase 2 of the trial, investors were disappointed by the overall outcome. In fact, some commenters have already accused Neruotrope of attempting to “spin” a negative story into something positive.
In order to get to the bottom of Neurotrope’s results, one must look at the company’s reporting methodology. While the company enrolled nearly 150 patients in its recent trial, today’s press release highlighted the results of a smaller group of patients that were administered the lower of two bryostatin doses.
In this subgroup of patients, there was an average increase in the Severe Impairment Battery (SIB) of 1.5 points over a three-month treatment regime. By comparison, the placebo group saw a decrease of 1.1 points. However, this 2.6 point difference was not statistically significant, and Neurotrope did not provide results for the patients who were treated with the higher dose of bryostatin.
Nevertheless, the company said the results of the study were strong enough to move bryostatin into a larger trial.
Bryostatin was discovered more than four decades ago and is obtained from a tiny sea organism that kind of looks like seaweed. The compound was initially thought to have anti-tumor effects, but clinical trials were ultimately disappointing.
However, recent animal trials suggested that bryostatin could help improve memory. Current Alzheimer’s therapies focus on treating symptoms, but it is hoped that bryostatin could target the underlying disease.
But today’s results are less-than-encouraging, and investors have reacted accordingly. Still, if and when the drug moves onto a larger trial group, investors should stay tuned to see if there is some hope left for bryostatin.
Looking for Ideas with Even Greater Upside?
Most of Zacks’ investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Neurotrope (NTRP) Stock Crashing Today?
Shares of Neurotrope Bioscience (NTRP - Free Report) opened more than 46% lower on Monday after the company released the results of its clinical trial for bryostatin, a drug candidate for patients with moderate to severe Alzheimer’s.
Although Neurotrope’s press release claims “positive top-line results” in Phase 2 of the trial, investors were disappointed by the overall outcome. In fact, some commenters have already accused Neruotrope of attempting to “spin” a negative story into something positive.
In order to get to the bottom of Neurotrope’s results, one must look at the company’s reporting methodology. While the company enrolled nearly 150 patients in its recent trial, today’s press release highlighted the results of a smaller group of patients that were administered the lower of two bryostatin doses.
In this subgroup of patients, there was an average increase in the Severe Impairment Battery (SIB) of 1.5 points over a three-month treatment regime. By comparison, the placebo group saw a decrease of 1.1 points. However, this 2.6 point difference was not statistically significant, and Neurotrope did not provide results for the patients who were treated with the higher dose of bryostatin.
Nevertheless, the company said the results of the study were strong enough to move bryostatin into a larger trial.
Bryostatin was discovered more than four decades ago and is obtained from a tiny sea organism that kind of looks like seaweed. The compound was initially thought to have anti-tumor effects, but clinical trials were ultimately disappointing.
However, recent animal trials suggested that bryostatin could help improve memory. Current Alzheimer’s therapies focus on treating symptoms, but it is hoped that bryostatin could target the underlying disease.
But today’s results are less-than-encouraging, and investors have reacted accordingly. Still, if and when the drug moves onto a larger trial group, investors should stay tuned to see if there is some hope left for bryostatin.
Looking for Ideas with Even Greater Upside?
Most of Zacks’ investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>